Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States.

Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients. Cardiac amyloidosis patients ≥18 years old hospitalized between 2014 and 2016 were identified in claims if they had ≥1 inpatient claim consistent with amyloidosis and evidence of cardiac dysfunction. Descriptive statistics were reported. 3239 cardiac amyloidosis patients [1795 (55.4%) with concurrent renal disease] were identified. Mean (SD) length of stay was 8.3 (11.1) days. 25.2% were admitted to the intensive care unit. Mean overall hospitalization costs were USD$20,584. In-hospital mortality was 9.0% overall. 16.8% were readmitted within 30 days, with 11.2% dying in-hospital and a mean readmission cost of USD$18,536. Hospitalization for cardiac amyloidosis is costly, with high rates of readmission and mortality. Opportunities exist to improve care.

Déclaration de conflit d'intérêts

Quock is an employee of Prothena Biosciences Inc, which funded the research described in this manuscript. D’Souza is an employee of the Medical College of Wisconsin and was paid by Prothena Biosciences Inc to consult as a subject matter expert. Yan, Tieu, and Broder are employees of Partnership for Health Analytic Research, LLC, which received funding from Prothena Biosciences Inc to conduct the research described in this manuscript. The authors report no other conflicts of interest in this work.